Over 2015, IDEA worked on the development of a revised QRA methodology (QRA2), focusing on total exposure of consumers to individual fragrances. For this purpose, a joint academia/industry IDEA working group has reviewed the uncertainties where a safety assessment factor (SAF) is warranted and the scientific basis for the assignment of each SAF value. Moreover, an aggregate exposure model based on actual consumer use of products which involves the utilization of these SAF values has been developed.
The work that resulted out of this science-based multi-stakeholder dialogue was presented at the IDEA Annual Review 2015 by Prof. Jim Bridges, Chair of the IDEA Supervisory Group, pointing out that the need was identified to now move on the implementation of the revised QRA and evaluate the feasibility to assess the effectiveness via monitoring of clinical data.
The working group met on February 15th, 2017 in Leuven, to follow up on the discussions initiated at their first meeting in 2016 on the objectives and on the protocol of such study.
The documentation related to the Working Group meeting is:
1. Surveillance study (status and plan) - Matthias Vey (IDEA Management Team)
2. Complimentary work (status and plan):
a) Factors to be considered in study development: Gauging the effectiveness of QRA - Joe Huggard (Consultant)
b) Details of current intervention study proposal - Anne Marie Api (RIFM)
3. Breakout group discussions:
The participants discussed the surveillance study and the intervention study in two breakout groups: